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Anti-HBs re-seroconversion after liver transplantation in a patient
with past HBV infection receiving a HBsAg positive graftq
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5Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, USABackground/Aims:Orthotopic liver transplantation (OLT) is an important therapeutic option for HBV-related end-
stage-liver disease, yet it is often hampered by a scarcity of organ availability. One option to increase organ availability
is the use of virologically compromised organs from HBV-infected donors. Transplantation of anti-HBcore positive grafts
has been associated with a low risk of HBV recurrence if adequately treated with nucleoside analogs, irrespective of con-
comitant HBV-speciﬁc immunoglobulin therapy. Experience using HBsAg positive grafts is, however, very limited.
Methods:Here, the analysis of the cellular and humoral HBV-speciﬁc immunity of a subject with past HBV infection
(anti-HBs and anti-HBc positive) receiving an HBsAg positive liver graft is reported.
Results:Nine months post-OLT, the patient experienced a spontaneous anti-HBs re-seroconversion allowing the discon-
tinuation of HBIG. The data show a concurrent increase in the cellular and humoral immunity at times of reduced viral
antigenemia, demonstrating eﬀective immune control of HBV post-OLT.
Conclusions:These data support the use of marginal organs in this setting, providing a potential strategy to further alle-
viate organ shortage.
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Keywords: Orthotopic liver transplantation; HBsAg positive marginal graft; Humoral immunity; T cell immunity; Organ
shortage0168-8278/$34.00  2008 European Association for the Study of the Liver.
doi:10.1016/j.jhep.2008.08.026
Received 22 April 2008; received in revised form 1 August 2008; accepted
27 August 2008
Associate Editor: P.-A. Clavien
q The authors declare that they do not have anything to disclose
regarding funding from industries or conﬂict of interest with respect to
this manuscript.
* Corresponding author. Tel.: +39 051 6363618; fax: +39 051
345806.
E-mail address: pietro.andreone@unibo.it (P. Andreone).
 These authors contributed equally to this work.
Abbreviations: OLT, orthotopic liver transplantation; ESLD, end-
stage liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus;
HBIG, hepatitis B immunoglobulin; ALT, alanine aminotransferase;
ELISpot, enzyme-linked immunospot.1. Introduction
Orthotopic liver transplantation (OLT) is an eﬀec-
tive therapeutic option for end-stage liver disease
(ESLD) and hepatocellular carcinoma, but survival
on the waiting list is hampered by the shortage of
available organs [1]. To overcome this limitation, so-
called ‘‘marginal grafts”, including organs from aged
donors or infected by hepatitis B (HBV) or C virus
(HCV) in case of HBV- or HCV-related ESLD, are
increasingly employed [1]. Liver grafts from HBV core
antibody-positive (anti-HBc) but HBV surface antigenPublished by Elsevier B.V. All rights reserved.
Table 2
Human Leucocyte Antigen (HLA) Typing of organ donor and recipient
performed by SS-PCR.
HLA-A
locus
HLA-B
locus
HLA-DRB1
Locus
Race
Recipient 02/03 18/70 16 Caucasian
Donor 01/02 39/62 13 Caucasian
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an overall low risk of HBV reactivation when treated
with nucleos(t)ide analogues [2–6]. However, de novo
infections, as deﬁned as HBV transmission from donor
to the recipient, can occur and rapid graft failure and
patient death have been reported [7,8]. In contrast to
livers from anti-HBc positive donors, the use of HBsAg
positive grafts is more limited, and the few available
studies or case reports yielded conﬂicting results [9–
11]. HBV-speciﬁc cellular and humoral immunity plays
a key role in the course and outcome of HBV infection
in immunocompetent patients [12]. Recent analyses of
the HBV-speciﬁc cellular immunity in OLT recipients
have shown a proﬁle similar to that of patients with
chronic HBV infection and suppressed HBV-DNA,
with a preferential targeting to the viral nucleocapsid
antigen [13]. These data indicate that transplanted sub-
jects can maintain or even develop new virus-speciﬁc
cellular immunity, contributing to viral control after
transplantation [13].
We report a case of a patient undergoing OLT for
HCV-related ESLD and past HBV infection (anti-
HBcore and anti-HBs positive) who received an
HBsAg-positive graft. The patient ﬁrst showed the sero-
logical appearance of HBsAg, with subsequent serocon-
version to anti-HBs antibodies nine months after
transplantation. Seroconversion was concomitant with
the increase in cellular immunity, suggesting that the
cooperation between the two arms of adaptive immunity
may eﬀectively control the virus.2. Case report
A 64-year-old man with HCV-related ESLD compli-
cated by several upper digestive bleedings and hepato-
renal syndrome was listed for OLT in August 2004 atTable 1
Amino acid sequence and protein location of peptides targeted by the
OLT recipient. A set of 208 overlapping peptides (OLP) was synthesized
covering the entire HBV proteome including the nucleocapsid protein (24
peptides), envelope (53 OLP), X-protein (20 OLP) and polymerase
protein (111 OLP) as described [13]. Peptides were adapted 18-mers
overlapping by 10 amino acids and were based on the reported HBV
genotype D reference strain ayw since HBV genotype D is predominant
in Italy. In addition, a previously described set of deﬁned HBV-derived
CD8 T cell epitopes was included [15]. Only sequences of peptides
targeted at least at one time point are shown (Table 2).
Peptide Sequences Protein
S17 LLVPFVQWF Envelope
D16 GRETVIEYLVSFGVWI Core
D17 YLVSFGVWIRTPPAY Core
Pol23 FLLAQFTSA Polymerase
Pol24 LLAQFTSAI Polymerase
D165 PMGVGLSPFLLAQFTS Polymerase
D166 FLLAQFTSAICSVVRR Polymerasethe Bologna Liver Transplantation Center (MELD
score 24). The main concomitant pre-OLT pathologies
included autoimmune hemolytic anemia requiring treat-
ment with steroids.
The serum HBV markers suggested a past exposure
to HBV, with positive serology for anti-HBs (320
mUI/mL) and anti-HBc IgG, and undetectable HBV-
DNA. In May 2005, because of signiﬁcant worsening
of liver function (MELD 27), after providing written
informed consent, the patient underwent OLT receiving
a partially HLA-matched HBsAg-positive liver graft
(Table 2) from a deceased donor, as from experimental
protocol launched by the Italian Health Authority on
2002 [14]. The HBV-DNA of the donor was positive
(190 UI/mL). The immunosuppressive regimen con-
sisted of tacrolimus and steroids (starting with a dosage
of 50 mg daily and tapered down over eight months and
stopped nine months post-OLT). To control post-OLT
HBV infection, 10’000 IU HBIG were infused during
the anhepatic phase, followed by 5’000 IU every other
day for the ﬁrst month, then 5’000 IU weekly for the sec-
ond month and subsequently 5’000 IU every 3–4 weeks
to maintain an anti-HBs titer above 250 IU/ml. In addi-
tion, lamivudine was started at day one post-OLT
(100 mg/daily) and continued throughout. Monitoring
of HBV serology and HBV-DNA was performed
monthly in the ﬁrst year post-OLT, and then every three
months thereafter (Table 3). HBsAg and HBV DNA
were undetectable and anti-HBs very high the ﬁrst threeTable 3
Serologic, virologic and biochemical time course after OLT.
Post-transplant
months
HBsAb
mUI/mL
HBsAg
UI/mL
HBV-DNA
UI/mL
ALT U/L
(0–40)
0 320 0.01 Not performed 19
2 6005 0.01 <3.3 42
3 2814 0.01 <3.3 87
3.5 54 7.59 <3.3 34
4 294 2.24 <3.3 33
5 503 1.63 <3.3 38
6 3500 2.24 <3.3 32
7 59 9.78 <3.3 32
8 375 3.09 <3.3 24
9 5237 0.25 <3.3 68
11 5901 0.42 <3.3 19
12 5236 0.55 <3.3 23
15 9145 0.15 <3.3 36
18 8290 0.04 <3.3 33
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passive immunoprophylaxis with HBIG, serum HBsAg
appeared 14 weeks post-OLT (3.5 month), with a con-
comitant decrease of anti-HBs levels to a minimum of
54 IU/L but without appearance of HBV-DNA or
increase of ALT (Fig. 1 and Table 3). Regardless of
HBIG and lamivudine treatment, HBsAg and anti-
HBs ﬂuctuated reciprocally between month four and
eight post-OLT, while serum HBV-DNA remained per-
sistently undetectable. At month eight, the last adminis-
tration of HBIG was performed since the anti-HBs
levels increased spontaneously thereafter (Fig. 1 and
Table 3). After month three, steroids were continuously
tapered and stopped at month nine post-OLT. From the
ninth month onwards, a progressive increase of anti-
HBs was associated with a concomitant decrease of
HBsAg levels until negativity at month 18 post-OLT.
During persistence of HBs antigenemia ALT levels
remained within normal ranges, except for only a slight
increase at month nine. At the time of writing, despite
HBIG interruption and lamivudine treatment, the
patient still presents high anti-HBs levels, negative
HBsAg and undetectable HBV-DNA. One-year post-0
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Fig. 1. Longitudinal time course of HBV virological and serological markers (1
(HBsAg; right Y axis and solid line) and ﬂuctuation in the titer for anti-HBs an
months post-transplantation. (B) HCV viral loads expressed as Meq per ml arOLT a biopsy was performed and documented, despite
HCV recurrence, only mild inﬂammation (Knodell score
6). HBsAg was focally detectable in rare hepatocytes
and HBV-DNA resulted positive.
To investigate whether the recovered humoral
immune response eight months post-OLT was accom-
panied by a similar boost in the cellular immunity,
HBV-speciﬁc T cell responses were comprehensively
assessed using an overlapping peptide set (208 peptides)
spanning the entire HBV genome before OLT as well
as three, nine and 12 months post-OLT (Fig. 2). Weak
responses to three individual peptides were detected in
the pre-OLT sample. These responses disappeared
three months post-OLT, and were not replaced by
other responses. However, nine months after OLT,
when steroid treatment was withdrawn, and a sharp
increase of the humoral response become evident, a
robust T cell activity directed against both polymerase
and envelope antigens was observed. Such a T cell
response then contracted again over the next three
months, together with a reduction in viral antigen bur-
den. The peptide sequences of the peptides with posi-
tive responses are shown in Table 1.10 11 12 13 14 15 16 17 18
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Fig. 2. Cellular HBV-speciﬁc immune responses over time: The breath and magnitude of HBV-speciﬁc T cell response to overlapping peptides (D165,
D16 and D17) and optimally deﬁned, HLA-A2 restricted CD8 T cell epitopes (s17, pol 23 and pol24) assessed by ELISpot assay at baseline and 9 and 12
months post-OLT are shown. At three months post-OLT no responses were detected (data not shown). The results are expressed as spot forming cells
(SCF) per million input cells after antigen-speciﬁc in vitro stimulation.
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3.1. Lymphocyte isolation and ELISpot assay
Peripheral blood mononuclear cells (PBMC) were isolated as
described [13], stimulated as outlined below and used in an interferon
gamma (IFN c) based enzyme-linked immunospot (ELISpot) assay at
100,000 PBMC/well. ELISpot assays for all time points were per-
formed at the same time and peptides were tested in 59 peptide matrix
pools as described previously [15]. Each test included 4 negative wells
(PBMC without peptides) and 1 positive well (PBMC stimulated with
phytoemoagglutinin). Results are expressed as spot forming cells
(SFC) per million cells and responses were considered positive when
exceeding all of the following criteria: (a) a minimum of 5 spots per
well; (b) mean of negative wells plus three times the standard deviation
of the negative wells and (c) three times the mean of the negative wells.
3.2. Antigen-speciﬁc T-cell expansion
5  10  106 cryopreserved PBMC were thawed and pulsed with
ﬁve diﬀerent peptide pools containing overlapping peptides spanning
either the nucleocapsid, envelope, X protein or polymerase protein
sequences or a set of previously described CD8 T cell epitopes. All pep-
tides were added at a ﬁnal concentration of 4 lg/ml per peptide.
Recombinant interleukin-2 (50 IU/ml) was added on day 3 and twice
a week thereafter. After 14 days of culture, cells were washed and
starved overnight in IL-2 free medium before using them in a IFNc-
based ELISpot assay [15].
3.3. Viral serology
HBsAg and anti-HBs titers were assessed by Chemiluminescent
Microparticle Immunoassay (CMIA) technology (Abbott Diagnostic,
Italy). For HBsAg, values above 0.05 UI/mL are considered positive;for anti-HBs values above 10 mUI/mL were considered protective.
HBV-DNA viral load was tested by real time quantitative PCR (Aﬃ-
gene, Alfa Wassermann, Italy) with a detection range of 3.3 IU/mL to
1.72  108 IU/mL. Quantitative assessment of HCV-RNA was per-
formed by branched DNA technology (bDNA) Versant HCV RNA
3.0 assay (Siemens, Italy), detection range from 3.200 to 4.0  107.
copies/mL.4. Discussion
The use of HBsAg positive liver grafts is currently pre-
cluded in most countries, because of the high risk of de
novo HBV infection post-OLT. However, this risk might
change in transplant recipients with a pre-OLT full
immunity against HBV i.e. those patients with positive
serology for anti-HBs and anti-HBc antibodies. While
in the era prior to antiviral prophylaxis the use of HBV
infected grafts was not a feasible option, the introduction
of nucleos(t)ide analogues together with HBIG substan-
tially improved the OLT outcome using anti-HBc grafts
[2,16–19]. However, the few available reports using
HBsAg positive grafts for OLT indicate that their use
requires a lot of caution and restriction, particularly in
recipients who are co-infected with HDV [10]. So far
no data are available on the outcome of this approach
in patients immunized against HBV pre-OLT, namely
with anti-HBs and anti-core positivity. Patients with past
HBV infection maintain not only the humoral immunity
against HBV but broad and multi-speciﬁc cellular
E. Loggi et al. / Journal of Hepatology 50 (2009) 625–630 629immune responses can been detected even years after
recovery from infection [20]. The case described here
showed a spontaneous anti-HBs re-seroconversion and
the capacity to produce anti-HBs goes together with a
boost of cellular immunity. Some hypotheses can be
oﬀered to explain this outcome: ﬁrst, the patient was nat-
urally immunized against HBV (past HBV infection)
before OLT; thus despite immune suppression he was
able to re-evoke an eﬃcient antiviral immune response
of both arms, humoral and cellular immunity against
HBV. Second, the presence of HCV co-infection might
have played a role in controlling HBV, as HCV can exert
an inhibitory eﬀect on HBV replication [21]. Finally and
importantly, the withdrawal of steroids may have con-
tributed to restoring the anti-HBV immunity since the
genome of HBV contains a glucocorticoid-responsive
element, that is responsible for an increase in serum
HBV-DNA levels and enhanced production of viral tran-
scripts including antigens on exposure to CCS [22].
OLT is generally performed across HLA mismatches
between organ donor and recipient. As a result, the pre-
existing virus-speciﬁc, recipient-HLA restricted T cells
responses might no longer exert an eﬀective immune
control on HBV-infected hepatocytes. Instead, donor-
HLA restricted responses may emerge, as described by
Rosen and colleagues [23]. In the present study, donor
and recipient were only matched for one class I allele
(i.e. HLA A2, Table 2). Thus, it is conceivable that
donor-HLA restricted, virus-speciﬁc T cell responses
could crucially contribute to viral control post-OLT.
Although more detailed analyses and large cohorts of
patients would be required to clarify this issue, we can
only speculate that a certain level of HLA match could
allow the recipient to use his previously established cel-
lular immunity to control HBV replication again. This is
in line with the reported higher risk for post-OLT HBV
recurrence in a context of complete HLA mismatch [24].
In summary, although limited to just one case, the
report suggests that on selected occasions liver trans-
plantation using HBsAg positive liver grafts is a possible
option for recipients fully immunized against HBV, in
other words with past HBV infection. We showed in this
case how the memory T and B cell immune response
helped to control the virus again. Considering the previ-
ous reports of OLT using HBsAg-positive grafts, to our
knowledge, this is the ﬁrst report of an anti-HBs and
anti-HBc positive transplant recipient, who, after receiv-
ing a HBsAg liver graft, developed a transient HBs anti-
genemia followed by a rapid restoration of T and B cell
immunity with spontaneous anti-HBs re-seroconversion
consistent with his pre-OLT anti-HBV immunity.
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